- Home
- AIRS vs CNTB Comparison
AIRS vs CNTB Comparison
Compare AIRS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | CNTB |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 128.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIRS | CNTB |
|---|---|---|
| Price | $1.93 | $2.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 631.1K | 110.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,350,000.00 | $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | $24,617.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $0.51 |
| 52 Week High | $12.00 | $3.28 |
Technical Indicators
Market Signals| Indicator | AIRS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 51.52 |
| Support Level | $1.85 | $2.09 |
| Resistance Level | $3.29 | $2.86 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 52.53 | 44.78 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.